Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Progenity (NASDAQ: PROG ) is a San Diego-based biotech company that specializes in gastrointestinal health and oral biotherapeutics. Right now the company has no real revenue to speak of and is burning through cash. I...
3 Dividend Stocks Worth Checking Out Right Now With all the focus on earnings and an improving job market, the stock market today is filled with upbeat news. Regardless, some would argue that investors should not overlook dividend stocks as well. For the most part, this would be...
Interest rates are at their lowest levels in history, creating major problems for retirees looking to the traditional 60/40 portfolio. With a 1.8% yield, and 4.3% CAGR inflation-adjusted consensus total return forecast, retirees might be in for lean times in the coming years and decad...
Miller/Howard Investments is an employee-owned, research-driven firm managing portfolios for a range of investors, from high-net-worth individuals to large institutions. We now hold Texas Instruments, NetApp, Broadcom, and Cisco, all of which have strong growth prospects, yet attracti...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There is a lot going on right now. Inflation is becoming a concern and the global supply chain has yet to recover from the pandemic, resulting in product shortages. Semiconductors continue to be in short supply , making su...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The allure of dividend stocks should be increasing right now. The Fed has signaled that it will soon begin tapering the market stimulus it provided during the pandemic. Following the news in late September, there hasn...
$229 million acquisition using only $22 million up-front. Low-risk, blockbuster potential GI assets acquired. Many upcoming near and medium-term catalysts. New mechanism of action defined for IBD (not a “me too” drug). Various indications “partner-able...
Amgen faces some issues similar to those faced by AbbVie. Amgen on the surface is at the same time more exposed, and the risk materializes later. However, there's something which will likely bring the risk forward to 2023 already. Finally, a risk is brewing for most large phar...
Kiplinger Investing publishes opportune source lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published on 6/1/21 and 9/9/21. 20 of the 37 out of 55 billionaire-held stocks pay dividends. As of 10/15/21, the top-ten ranged 1.35%-5.43% by annual yie...
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns. But, what if, instead… they could “...
News, Short Squeeze, Breakout and More Instantly...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....
2024-04-30 09:59:20 ET The stock market is where investors trade shares of publicly traded companies. Among various investment options, dividend stocks are popular for their potential to provide income through regular dividend payments. These stocks are often shares of well-established ...
2024-04-29 11:00:06 ET Evan Seigerman from BMO Capital issued a price target of $180.00 for ABBV on 2024-04-29 09:49:00. The adjusted price target was set to $180.00. At the time of the announcement, ABBV was trading at $158.5841. The overall price target consensus is at...